CardioMEMS HF System

Remote Pulmonary Pressure Monitoring

CardioMEMS HF System

CardioMEMS Patient Selection & Assessment

Selecting the Right Patient for Remote PA Pressure Monitoring

The CardioMEMS™ HF System is indicated for patients with:1

  • NYHA Class II or Class III heart failure; and
  • One heart failure hospitalization in the past 12 months; and/or
  • Have elevated natriuretic peptides


The CardioMEMS HF System is contraindicated for patients with:

  • An inability to take dual antiplatelet or anticoagulants for one-month post implant

CardioMEMS PA Pressure Monitoring Resources

This document provides information to select heart failure patients who would benefit most from the CardioMEMS HF System, along with BNP thresholds.

CardioMEMS PA pressure monitoring selection resources

Patients who most commonly receive the CardioMEMS HF System are those on GDMT and those who exhibit any of the following:2

  • Fluid volumes that are hard to know or manage
  • Challenging physical assessment
  • Is a patient with HFpEF or HFrEF
  • Compliant with heart failure medical care
  • Would benefit from remote monitoring if they live far from a clinic

Note: The CHAMPION trial specifically excluded patients with American College of Cardiology/ American Heart Association stage D heart failure who needed advanced therapies (i.e., left ventricular assist device, transplant or inotropic support). Even if inotropic support improved heart failure symptoms, a patient would still be defined as stage D, with refractory heart failure.2

NYHA Classes of Heart Failure

Stages of Heart Failure
Reimbursement & Coding

Reimbursement & Coding

Manuals & Resources

Manuals & Resources

Customer Service

Customer Service


  1. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. The Lancet. 2021;398:991-1001.
  2. Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M., Costanzo, M. R., Stevenson, L. W., …Yadav, J. S., for the CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666.

MAT-2006770 v9.0